Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study

Prostate cancer (PrCa) is the second most prevalent malignancy in men worldwide. Observational studies have linked the use of low-density lipoprotein cholesterol (LDL-c) lowering therapies with reduced risk of PrCa, which may potentially be attributable to confounding factors. In this study, we perf...

Full description

Saved in:

Bibliographic Details
Published in:	PLoS medicine Vol. 20; no. 1; p. e1003988
Main Authors:	Fang, Si, Yarmolinsky, James, Gill, Dipender, Bull, Caroline J., Perks, Claire M., Davey Smith, George, Gaunt, Tom R., Richardson, Tom G.
Format:	Journal Article
Language:	English
Published:	United States Public Library of Science 03.01.2023 Public Library of Science (PLoS)
Subjects:	Age Analysis Biobanks Biology and Life Sciences Body mass index Cancer Cardiovascular disease Care and treatment Cholesterol Cholesterol, LDL Consortia Drug targeting Gene expression Genes Genetic analysis Genetic aspects Genetic diversity Genetics Genome-wide association studies Genome-Wide Association Study Genomes Genomics Health aspects Humans Lipids Lipoprotein A Liver Low density lipoprotein Low density lipoproteins Male Malignancy Medicine and Health Sciences Mendelian Randomization Analysis Observational studies Oncology, Experimental Plasma levels Polymorphism, Single Nucleotide Prevention Proprotein Convertase 9 - genetics Prostate cancer Prostatic Neoplasms - genetics Risk factors Single nucleotide polymorphisms Single-nucleotide polymorphism Statins Testosterone Therapeutic targets Variables United Kingdom United Kingdom > UK
ISSN:	1549-1676, 1549-1277, 1549-1676
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!